Totient

Totient is an AI-driven biotechnology company that leverages tertiary lymphoid structures (TLSs) to identify novel tissue-specific antigens and develop matching high-affinity antibody therapeutics. It uses machine learning and immunoinformatics technology to pull critical insights from large, complex datasets, to quickly and accurately assemble the most potent antibody candidates. The unique applicability of the Totient platform allows the company to remain flexible and develop therapeutics for cancer, autoimmune disease, infections, and viruses.

It was founded in 2017 and is based in Cambridge, Massachusetts.

Totient headquartered in United States, North America, operates in the Biotechnology, Artificial Intelligence (AI), Machine Learning, Life Science sector. The company focuses on Biotechnology and has secured $320.0M in funding across 32 round(s). With a team of 1-10 employees, Totient is actively contributing to advancements in Biotechnology. Their latest funding round, Seed Round - Totient, raised $10.0M. Discover more about their projects, partnerships, and impact on our platform.